Solid Biosciences Inc.
SLDB
$5.93
$0.274.77%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | 25.95% | 25.95% | 25.95% | 259.62% | 116.92% |
Gross Profit | -25.95% | -25.95% | -25.95% | -259.62% | -116.92% |
SG&A Expenses | 19.83% | 21.54% | 19.98% | 30.80% | 21.05% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 56.78% | 44.15% | 24.36% | 5.66% | -3.92% |
Operating Income | -56.78% | -44.15% | -24.36% | -5.66% | 3.92% |
Income Before Tax | -69.90% | -54.77% | -29.87% | -12.78% | -0.48% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -69.90% | -54.77% | -29.87% | -12.78% | -0.48% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -69.90% | -54.77% | -29.87% | -12.78% | -0.48% |
EBIT | -56.78% | -44.15% | -24.36% | -5.66% | 3.92% |
EBITDA | -58.84% | -44.85% | -25.10% | -6.53% | 3.63% |
EPS Basic | 15.20% | 24.08% | 37.27% | 40.94% | 51.59% |
Normalized Basic EPS | 15.20% | 24.14% | 37.31% | 47.78% | 55.95% |
EPS Diluted | 15.20% | 24.08% | 37.31% | 40.98% | 51.62% |
Normalized Diluted EPS | 15.20% | 24.14% | 37.31% | 47.78% | 55.95% |
Average Basic Shares Outstanding | 104.91% | 95.11% | 105.27% | 98.89% | 104.96% |
Average Diluted Shares Outstanding | 104.91% | 95.11% | 105.27% | 98.89% | 104.96% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |